Hexetidine

Summary

Hexetidine (CHEMBL144673) is an approved small molecule (ATC G01AX16); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AX16 (+1 more)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 339.6 Da · C21H45N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL144673
Name	Hexetidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3607
ATC	G01AX16, A01AB12
Molecular formula	C21H45N3
Molecular weight	339.6
InChIKey	DTOUUUZOYKYHEP-UHFFFAOYSA-N

SMILES: CCCCC(CC)CN1CC(CN(C1)CC(CC)CCCC)(C)N

IUPAC name: 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine

Also known as: Hexetidina, Hexetidine, NSC-17764, Oraldene, Sterisil, SID26748327, SID144203975, SID93576718, HEXETIDINE, SID170465729, hexetidine

Patent coverage: 4,236 distinct patent families (16,066 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Alpha-2A adrenergic receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Mu-type opioid receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	6.12	AC50	750	nM	CHEMBL_ACT_25117649
CHRM2	5.5	AC50	3183	nM	CHEMBL_ACT_25195759
HTR1A	5.46	AC50	3439	nM	CHEMBL_ACT_25165047
SLC6A3	5.34	AC50	4598	nM	CHEMBL_ACT_25124982
DRD3	5.32	AC50	4844	nM	CHEMBL_ACT_25194546
OPRM1	5.31	AC50	4862	nM	CHEMBL_ACT_25158198
SLC6A4	5.19	AC50	6510	nM	CHEMBL_ACT_25151350
SLC6A2	5.1	AC50	7934	nM	CHEMBL_ACT_25146023
CHRM1	5.01	AC50	9849	nM	CHEMBL_ACT_25210232

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01115049	PHASE4	COMPLETED	Hexetidine and Chlorobutanol for Lesions Due to Prostheses

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).